Physics Bucharest 2017

ASCENDE- RT trial

BUT higher late G3+ GU ( 18% in BT boost arm vs. 8% in EBRT alone )

Most strictures and urinary incontinence

Recommended boost dose reduced to 110Gy

Morris WJ, et al. ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam radiiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable- riisk localized prostate cancer. JCO 2015;33 (suppl 7) abstr 3.